CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
2.450
-0.030 (-1.21%)
Feb 21, 2025, 4:00 PM EST - Market closed
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 176 employees as of December 31, 2023. The number of employees decreased by 48 or -21.43% compared to the previous year.
Employees
176
Change (1Y)
-48
Growth (1Y)
-21.43%
Revenue / Employee
$125,313
Profits / Employee
-$175,938
Market Cap
37.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CASI News
- 6 weeks ago - CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Accesswire
- 3 months ago - CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - Accesswire
- 4 months ago - CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Accesswire
- 6 months ago - CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - PRNewsWire
- 6 months ago - CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 7 months ago - CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - PRNewsWire
- 8 months ago - CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - PRNewsWire
- 8 months ago - CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company - PRNewsWire